According to the news outlet, a doctor at Mount Sinai West Medical Center in New York inserted a "1.5-inch-long implant consisting of wires and electrodes into a blood vessel in the brain of an ALS patient" on July 6.

In August 2020, Synchron becomes the first brain-computer interface (BCI) company to receive the FDA's approval to conduct an investigational device exemption (IDE) clinical trial of a permanently implanted device.

NIH awarded Synchron $10 million to begin a US trial of a brain implant that allows users to manage digital apps using only their thoughts, as reported by Fierce Biotech.

"Our neuroprosthetics are designed to help people get their lives back by restoring lost functions," Synchron wrote on its website.

According to its website, the product is called brain.io™ – "a motor neuroprosthesis designed to bypass damaged neural pathways in patients with severe paralysis, allowing them to restore motor capabilities including control of digital devices."

The procedure consists of the following steps:

The stentrode™ is an endovascular implant, placed in a vein alongside the motor cortex which generates any signal related to movement.

A receiver device implanted in the chest transmits the neural signals to a decoder.

A machine learning algorithm translates those signals into specific digital commands.